Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Impact
The implications of S1327 on state laws include amendments to the existing prescription monitoring program established under P.L.2007, c.244. By establishing a mechanism for patients to express their wishes regarding opioid prescriptions, the bill seeks to improve the management of prescriptions and address the growing concern of substance abuse. This could lead to better-informed prescribing practices among healthcare providers and potentially reduce the risk of addiction or misuse of controlled substances.
Summary
Senate Bill S1327 aims to enhance patient autonomy by allowing individuals to indicate their preference not to be prescribed opioid drugs or other controlled substances that have a high potential for abuse. The bill requires the Division of Consumer Affairs within the Department of Law and Public Safety to create a formal process enabling patients to request that their prescription monitoring information reflect this preference. Notably, this indication would be made at the patient's discretion, emphasizing the importance of patient consent and autonomy in treatment decisions. Additionally, the bill outlines procedures for patients to remove such indications if they choose to do so later.
Contention
While S1327 is primarily framed as a means to aid recovery and ensure better patient outcomes, some potential points of contention could arise regarding the responsibilities of healthcare providers. Questions may emerge about how practitioners will verify and honor a patient's request, especially in emergency situations where a patient's ability to communicate may be compromised. Additionally, concerns may be raised about the implications for patients who may genuinely require pain management but have previously indicated a preference against certain medications.
Same As
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Permits patients to indicate that they should not be prescribed opiates and certain other controlled substances in prescription monitoring program information.
Requires prescriptions for animals to be issued in name of animal owner; prohibits unnamed persons from possessing prescribed drugs; and requires Prescription Monitoring Program to include information about controlled substances prescribed by veterinarians.
Requires hospital and emergency room physicians to consult the prescription monitoring program registry and to notify a patient's prescriber that such patient is being treated for a controlled substance overdose.
Expands definition of personal data to include use of reproductive health care services and prohibits collection of reproductive health care prescription drugs from Prescription Monitoring Program.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.